Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

BridgeBio Pharma (BBIO) Non Operating Income (2019 - 2025)

BridgeBio Pharma (BBIO) has disclosed Non Operating Income for 7 consecutive years, with -$240.3 million as the latest value for Q4 2025.

  • Quarterly Non Operating Income fell 698.87% to -$240.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$394.2 million through Dec 2025, down 322.6% year-over-year, with the annual reading at -$209.1 million for FY2025, 511.77% down from the prior year.
  • Non Operating Income hit -$240.3 million in Q4 2025 for BridgeBio Pharma, down from -$41.3 million in the prior quarter.
  • In the past five years, Non Operating Income ranged from a high of $100.0 million in Q2 2024 to a low of -$240.3 million in Q4 2025.
  • Historically, Non Operating Income has averaged -$15.9 million across 5 years, with a median of -$9.4 million in 2021.
  • Biggest five-year swings in Non Operating Income: tumbled 7700.0% in 2021 and later soared 1677.87% in 2024.
  • Year by year, Non Operating Income stood at $28.3 million in 2021, then tumbled by 264.01% to -$46.4 million in 2022, then skyrocketed by 115.28% to $7.1 million in 2023, then soared by 466.18% to $40.1 million in 2024, then tumbled by 698.87% to -$240.3 million in 2025.
  • Business Quant data shows Non Operating Income for BBIO at -$240.3 million in Q4 2025, -$41.3 million in Q3 2025, and -$47.4 million in Q2 2025.